Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.14B P/E - EPS this Y -14.00% Ern Qtrly Grth -
Income -174.61M Forward P/E -6.50 EPS next Y -12.70% 50D Avg Chg -15.00%
Sales - PEG -0.29 EPS past 5Y - 200D Avg Chg 12.00%
Dividend N/A Price/Book 2.55 EPS next 5Y 11.00% 52W High Chg -32.00%
Recommedations 1.90 Quick Ratio 13.22 Shares Outstanding 105.91M 52W Low Chg 347.00%
Insider Own 0.67% ROA -22.25% Shares Float 67.92M Beta 1.00
Inst Own 100.84% ROE -36.50% Shares Shorted/Prior 6.94M/6.84M Price 15.59
Gross Margin - Profit Margin - Avg. Volume 1,359,682 Target Price 30.63
Oper. Margin - Earnings Date Nov 6 Volume 552,846 Change -0.32%
About 89bio, Inc.

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

89bio, Inc. News
11/15/24 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
11/12/24 89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
11/12/24 89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
11/07/24 89bio Reports Third Quarter 2024 Financial Results and Corporate Updates
11/05/24 89bio to Participate in the UBS Global Healthcare Conference
11/02/24 Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH
11/01/24 Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
10/18/24 Suvretta Capital Management's Strategic Reduction in 89bio Inc Holdings
10/17/24 State Street Corp's Strategic Acquisition in 89bio Inc
10/15/24 89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
10/11/24 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/30/24 89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
09/16/24 89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
08/29/24 89bio to Participate in Upcoming Investor Conferences
08/07/24 89bio Appoints Francis Sarena as Chief Operating Officer
08/05/24 89bio Appoints Charles McWherter, Ph.D., to its Board of Directors
05/22/24 89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
05/14/24 89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
05/10/24 89bio Inc (ETNB) Reports Increased Losses in Q1 2024 Despite Advancements in Clinical Trials
05/09/24 89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
ETNB Chatroom

User Image Bornjever Posted - 8 hours ago

$ETNB $IGMS MYNZ is a very strong medical company in testing area and all of us could benefit from the technology and the investment. I am very excited in sober way and I hope for sake of all of us this comes to fruition for benefit of all.

User Image Solene__Frost Posted - 1 day ago

$ETNB $IGMS LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image Quantumup Posted - 2 days ago

Citi (11/18/2024)🏁 $AKRO Buy/$65—FGF21RA Efruxifermin has shown compelling efficacy4 #MASH that's likely2support meaningful⬆️take; is likely2differentiate in cirrhotic MASH; is well-positioned ahead of the impending GLP-1 entrance in MASH,🎯g a different subset of pts: $iva $vktx $mdgl $etnb

User Image FetchDog Posted - 2 days ago

$ETNB Looks like a higher low was achieved today (relative to yesterday's low). So if this makes a higher high by rising above $8.02, the price should start an uptrend. The pattern of 1) good news with a price rise, 2) offering with a price drop and finally 3) price recovery is a fairly reliable pattern, especially when the stock is a "quality" stock that institutions like to own. For example, look at what happened to $VERA recently. Of course, no guaranties, just probabilities. I entered ETNB long today.

User Image Bornjever Posted - 2 days ago

$ETNB yes the change on valuation is crazy where a bribe was not paid or whatever and millions of shares sell immediately!!!

User Image Dahlcr Posted - 5 days ago

$ETNB Goldman Sachs is the stock price killer. Our stock is trading at 10.50, Goldman comes in and does a secondary at $8.50. Time after time Goldman has done this with stocks I own. When GS gets involved with your stock in might be time to sell.

User Image dwarf_vader Posted - 6 days ago

$ETNB what have I missed? I thought they got positive results

User Image JohannaTurner Posted - 6 days ago

$ETNB $IGMS MYNZ Wow, this is insane news! Don't miss out. The train is leaving the station. Add it to your watchlist to see what happens next. 😏

User Image DonCorleone77 Posted - 1 week ago

$ETNB 89bio 11.46M share Spot Secondary priced at $8.50 The deal size was increased to $125M from $100M and priced below last closing price of $9.05. Goldman Sachs, Leerink and Evercore ISI are acting as joint book running managers for the offering.

User Image All_just_a_game Posted - 1 week ago

$AKRO $ETNB $VKTX $ALT Is the thesis that bone density loss is correlated to muscle mass loss? Not sure all the GLP trials are actually testing for bone density? I know this is a red flag 🚩 for the FGF21 class. https://www.cnbc.com/amp/2024/11/12/amgen-stock-falls-on-weight-loss-drugs-bone-density-loss-data.html

User Image mrmarvyn Posted - 1 week ago

$ETNB is today's drop due to AbbVie's disappointment yesterday with their Phase 2 drug?

User Image bobby8struja Posted - 1 week ago

$ETNB earnings killed it

User Image Truet67 Posted - 1 week ago

💥 Boom 🚨 Big news! LFGOOOOOO! Mainz Biomed MYNZ has teamed up with Thermo Fisher TMO (mkt cap $209.2B, trading at ~$546.92) to develop a next-gen colorectal cancer screening tool for global markets. Thermo Fisher’s $42.4B annual revenue and advanced tech will boost MYNZ’s mRNA-based assays, hitting 85% detection for advanced adenomas vs. competitors’ 43% and 20%. With CRC cases up 500% in young people, MYNZ is leading early detection. Win-win for both sides — TMO stepping into the CRC market too. Big developments ahead! Calling all apes, let's crush these shorties—this time is bull time. Insane news, we've been waiting for!!! $ETNB $IGMS

User Image YakoCapital Posted - 1 week ago

$ETNB MDGL - MC $7.4 B AKRO - MC $2.3 B ETNB - MC $1.09 B ----> Lots of room to grow!

User Image Adelyn_Fish Posted - 1 week ago

MYNZ 🔥 Perfect time to jump in, cheapest dip!!! Shorts volume increased. Low Float only 29M outstanding shares. Any buy-in will make this fly to the moon. Here is why… 1.Frankie Muniz backing Mainz (yes, the Malcolm guy & NASCAR #33 now repping MYNZ). 2.Petra, ex-Obama advisor, hinted at a big U.S. lab partner. Solid source! 3.Six news hits in 3 weeks—momentum. 4.Already solid in the EU, not new but expanding, with insurance covering their tests. 5.Their test has 88% accuracy vs. EXAS (42%) & GH (20%)—big edge! 6.$1.5M private placement in the bag. 7.CEO teased big plans ahead. 8.Offering Deal $ETNB $IGMS

User Image hbwalk2 Posted - 1 week ago

@aaronr @WSRX yes. I agree. I actually thouhht i was talking a responding to $ETNB 🤣

User Image Kelly12 Posted - 1 week ago

$ETNB Blackrock bot 7.5m shares 9/30 I’m thinking buyout??? Maybe TEVA acquires it back?

User Image Shlobby Posted - 1 week ago

$ETNB got stopped out at the lows of course

User Image Shlobby Posted - 2 weeks ago

$ETNB starter

User Image Shlobby Posted - 2 weeks ago

$ETNB decent r/r here

User Image YakoCapital Posted - 2 weeks ago

$ETNB $10

User Image YakoCapital Posted - 2 weeks ago

$ETNB $12 then $17

User Image ctenidae Posted - 2 weeks ago

$ETNB Great stack up of events here. $MDGL spent all their time differentiating from GLP1, ENIGHTEN is going to read out with GLP1 use specifically called out. Peg can now leapfrog to be the go-to choice alongside or absent a GLP1. There's a lot of room in that market, but it's a nice jumpstart. Assuming Peg+GLP isn't worse, of course.

User Image MorenitaScorp Posted - 2 weeks ago

$ETNB ⌚️

User Image insiderbuyingselling Posted - 2 weeks ago

$ETNB new insider selling: 27955 shares. http://insiderbuyingselling.com/?t=ETNB

User Image nastento Posted - 2 weeks ago

@valueforme @GXD_Texas $ETNB had a great day which may have correlated with these comments?

User Image Theflash88 Posted - 2 weeks ago

$ETNB Triple the volume! Something is up.. added .

User Image Czreri1 Posted - 2 weeks ago

$ETNB the next $DRUG

User Image Ohzipit Posted - 2 weeks ago

$ETNB $MDGL $VKTX RJ comments this morning.

User Image steven1x Posted - 2 weeks ago

$ETNB https://www.sec.gov/Archives/edgar/data/1785173/000195004724007945/xsl144X01/primary_doc.xml

Analyst Ratings
Cantor Fitzgerald Overweight Sep 20, 24
Raymond James Strong Buy Aug 6, 24
RBC Capital Sector Perform Aug 6, 24
HC Wainwright & Co. Buy Aug 6, 24
Cantor Fitzgerald Overweight Jul 1, 24
Cantor Fitzgerald Overweight Jun 17, 24
Cantor Fitzgerald Overweight Jun 12, 24
HC Wainwright & Co. Buy Jun 11, 24
Cantor Fitzgerald Overweight May 17, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
LAPORTE KATHLEEN Director Director Jul 17 Sell 18.8 12,500 235,000 07/18/23
LAPORTE KATHLEEN Director Director Jul 17 Option 2.64 12,500 33,000 12,500 07/18/23
PALEKAR ROHAN Chief Executive Offi.. Chief Executive Officer Jun 05 Sell 20 15,000 300,000 286,978 06/07/23
PALEKAR ROHAN Chief Executive Offi.. Chief Executive Officer Jun 05 Option 1.93 15,000 28,950 301,978 06/07/23
Le-Nguyen Quoc See Remarks See Remarks May 09 Sell 18.11 13,683 247,799 164,971 05/11/23
Le-Nguyen Quoc See Remarks See Remarks May 09 Option 3.11 79,571 247,466 178,654 05/11/23
RA CAPITAL MANAGEMENT, L.P. Director Director Mar 24 Buy 16.25 2,461,538 39,999,992 11,081,584 03/30/23
Martins Ryan Chief Financial Offi.. Chief Financial Officer Mar 23 Sell 16.11 5,000 80,550 53,578 03/27/23
PALEKAR ROHAN Chief Executive Offi.. Chief Executive Officer Mar 23 Sell 16.00 15,000 240,000 269,080 03/27/23
Atkinson Edward Morrow III Director Director Mar 01 Sell 13.6 10,000 136,000 03/03/23
Atkinson Edward Morrow III Director Director Mar 01 Option 4.44 10,000 44,400 10,000 03/03/23
Martins Ryan Chief Financial Offi.. Chief Financial Officer Feb 17 Sell 13.89 2,540 35,281 58,578 02/22/23
Martins Ryan Chief Financial Offi.. Chief Financial Officer Feb 08 Sell 14.41 1,480 21,327 32,868 02/10/23
Martins Ryan Chief Financial Offi.. Chief Financial Officer Feb 03 Sell 12.91 3,592 46,373 35,368 02/07/23
Martins Ryan Chief Financial Offi.. Chief Financial Officer Feb 03 Option 3.11 3,000 9,330 38,960 02/07/23
Martins Ryan Chief Financial Offi.. Chief Financial Officer Jan 03 Sell 12.51 5,947 74,397 36,368 01/05/23
RA CAPITAL MANAGEMENT, L.P. Director Director Oct 18 Buy 7.65 1,172,741 8,971,469 8,955,410 10/20/22
PALEKAR ROHAN Chief Executive Offi.. Chief Executive Officer Sep 08 Option 1.93 100,000 193,000 197,623 09/09/22
RA CAPITAL MANAGEMENT, L.P. Director Director Jul 01 Buy 3.55 2,816,900 9,999,995 7,782,669 07/06/22
PALEKAR ROHAN Chief Executive Offi.. Chief Executive Officer Jan 27 Buy 6.82 7,500 51,150 45,845 01/31/22
ORBIMED ADVISORS LLC 10% Owner 10% Owner Jan 25 Sell 8.39 70,573 592,107 1,829,436 01/27/22
Waisbourd Ram See Remarks See Remarks Nov 16 Option 1.93 7,000 13,510 7,000 11/18/21
Waisbourd Ram See Remarks See Remarks Nov 16 Sell 16.49 7,000 115,430 11/18/21